Category: MSA, PSP, CBS: Neuroimaging
Objective: In this study, we aimed to compare the patterns of 18Fluorodeoxyglucose PET (FDG-PET) with 18F-Florzolotau PET in patients with Corticobasal Syndrome (CBS), and investigate whether tau deposition could affect brain metabolism in vivo.In this study, we aimed to compare the patterns of 18Fluorodeoxyglucose PET (FDG-PET) with 18F-Florzolotau PET in patients with Corticobasal Syndrome (CBS) and investigate whether tau deposition could affect brain metabolism in vivo.
Background: CBS is a clinical phenotype that characterized by changes in motor function and cognition. Numerous clinicopathologic studies revealed heterogenous neuropathologies in CBS, including CBD, AD, PSP, FTD and so on. Recent studies reported that 18F-FDG PET and tau-PET might help in the etiology diagnosis of CBS, however, whether tau deposition in vivo could affect brain metabolism still remained unclear.
Method: The study consecutively enrolled 100 patients clinically diagnosed with CBS in Huashan Hospital, Fudan University from Dec 2019 to Oct 2020. These patients had undergone both 18F-FDG PET and 18F-Florzolotau PET. According to the established visual reading methods, three experienced readers followed the next steps, blinded to each other. Firstly, the reader distributed CBS patients into different groups merely according to the pattern of 18F-FDG PET. Secondly, CBS patients were reclassified into different groups based on the visual analysis of 18F-Florzolotau PET and 18F-FDG PET images. Finally, the reader would evaluate the compatibility of 18F-FDG and 18F-Florzolotau PET images from the perspective of grouping, different brain regions and asymmetry.
Results: Patients with CBS presented heterogenous patterns of 18F-FDG PET and 18F-Florzolotau PET. According to either 18F-FDG PET or 18F-Florzolotau PET, they could be grouped into CBS-AD, CBS-CBD, CBS-PSP, CBS-FTD and others consistently. However, the consistency of 18F-FDG PET and 18F-Florzolotau PET varies in different groups of CBS, indicating that tau deposition plays different degrees of roles on brain metabolism in CBS with different etiology.
Conclusion: The combination of 18F-FDG PET and 18F-Florzolotau PET showed potential to the etiological classification of CBS, indicating that the advancing multimodal subtyping holds promise to target specific pathologies and offer precise distribution of therapeutic strategies for CBS.
To cite this abstract in AMA style:
X. Li, JY. Lu, FT. Liu, J. Wang. The heterogenous compatibility of FDG-PET patterns and tau deposition in vivo in patients with Corticobasal Syndrome [abstract]. Mov Disord. 2025; 40 (suppl 1). https://www.mdsabstracts.org/abstract/the-heterogenous-compatibility-of-fdg-pet-patterns-and-tau-deposition-in-vivo-in-patients-with-corticobasal-syndrome/. Accessed October 5, 2025.« Back to 2025 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/the-heterogenous-compatibility-of-fdg-pet-patterns-and-tau-deposition-in-vivo-in-patients-with-corticobasal-syndrome/